30 pharmas including Hanmi Pharm challenge the ‘diabetic neuropathy therapy market’
Since ‘Dexid(generic name: R-thioctic acid tromethamine),’ a diabetic neuropathy therapy, was expired for the PMS(Post-Marketing Surveillance), 30 pharmaceutical companies including Hanmi Pharm and Chong Kun Dang are reportedly getting ready to launch its generic.
‘Dixid’ is an incrementally mod...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
